NCT02932605 (CANGLIA) is a NA clinical trial of Cannabidiol in Schizophrenia, sponsored by UMC Utrecht.

Who is sponsoring NCT02932605?

NCT02932605 is sponsored by UMC Utrecht.

What drugs are being tested in NCT02932605?

Interventions in NCT02932605: Placebo, Cannabidiol.

What condition does NCT02932605 study?

NCT02932605 studies Schizophrenia.

Is NCT02932605 still recruiting?

NCT02932605 is currently completed. Last updated 27 March 2020.

Last reviewed 2020-03-27 · How we verify

NCT02932605: CANGLIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia

Completed NA Last updated 27 March 2020

What this trial tests

NA trial testing Placebo in Schizophrenia in 32 participants. Completed in 31 January 2020.

Timeline

3 November 2017

Primary endpoint
31 January 2020

31 January 2020

Quick facts

Lead sponsor	UMC Utrecht
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	32
Start date	3 November 2017
Primary completion	31 January 2020
Estimated completion	31 January 2020
Sites	1 location across Netherlands

Drugs / interventions tested

Placebo
Cannabidiol (CANNABIDIOL) — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

UMC Utrecht — full company profile →

Who can join

Adults 16 to 40, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.
Chesney E, Oliver D, McGuire P. · · 2022 · cited 28× · PMID 34255100 · DOI 10.1007/s00213-021-05905-9

Verify or expand the search:

Other trials of Cannabidiol

Trials testing the same drug.

NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress · Phase 1, PHASE2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other UMC Utrecht trials

Trials by the same sponsor.

NCT07512336 — A Randomized Intra-Patient Controlled Trial of MagnetOs™ Putty vs Autograft in Instrumented Posterolateral Spinal Fusion · NA · not yet recruiting
NCT07485985 — Coronary Sinus Reducer Therapy for Persisting Angina · NA · not yet recruiting
NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
NCT05375708 — Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Me · Phase 2 · suspended
NCT06898541 — Coronary Sinus Reducer in Coronary Microvascular Disease · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02932605 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UMC Utrecht
Last refreshed: 27 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02932605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing